The Phosphate Binder Ferric Citrate and Mineral Metabolism and Inflammatory Markers in Maintenance Dialysis Patients: Results From Prespecified Analyses of a Randomized Clinical Trial.

ABSTRACT:

Background

Phosphate binders are the cornerstone of hyperphosphatemia management in dialysis patients. Ferric citrate is an iron-based oral phosphate binder that effectively lowers serum phosphorus levels.

Study design

52-week, open-label, phase 3, randomized, controlled trial for safety-profile assessment.

Setting & participants

Maintenance dialysis patients with serum phosphorus levels ≥6.0 mg/dL after washout of prior phosphate binders.

Intervention

2:1 randomization to ferric citrate or active control (sevelamer carbonate and/or calcium acetate).

Outcomes

Changes in mineral bone disease, protein-energy wasting/inflammation, and occurrence of adverse events after 1 year.

Measurements

Serum calcium, intact parathyroid hormone, phosphorus, alumin

SUBMITTER: Van Buren PN 

PROVIDER: S-EPMC4868355 | biostudies-literature | 2015 Sep

REPOSITORIES: biostudies-literature